RiverPark Advisors LLC Buys 19,322 Shares of Zoetis Inc. (NYSE:ZTS)

RiverPark Advisors LLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 18.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 123,641 shares of the company’s stock after buying an additional 19,322 shares during the period. Zoetis makes up approximately 3.2% of RiverPark Advisors LLC’s holdings, making the stock its 8th largest holding. RiverPark Advisors LLC’s holdings in Zoetis were worth $19,471,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. FIL Ltd boosted its position in shares of Zoetis by 71.4% in the 4th quarter. FIL Ltd now owns 339,900 shares of the company’s stock worth $56,254,000 after buying an additional 141,631 shares in the last quarter. Sittner & Nelson LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at about $51,000. ExodusPoint Capital Management LP grew its position in shares of Zoetis by 17.9% in the fourth quarter. ExodusPoint Capital Management LP now owns 6,169 shares of the company’s stock valued at $1,021,000 after purchasing an additional 937 shares during the last quarter. Engineers Gate Manager LP increased its stake in shares of Zoetis by 151.1% during the 4th quarter. Engineers Gate Manager LP now owns 8,111 shares of the company’s stock worth $1,342,000 after purchasing an additional 4,881 shares in the last quarter. Finally, Schroder Investment Management Group lifted its stake in Zoetis by 9.5% in the 4th quarter. Schroder Investment Management Group now owns 423,633 shares of the company’s stock valued at $70,111,000 after buying an additional 36,659 shares in the last quarter. 90.03% of the stock is currently owned by institutional investors and hedge funds.

ZTS traded up $2.31 during trading on Thursday, hitting $200.35. 18,352 shares of the company’s stock were exchanged, compared to its average volume of 1,766,974. Zoetis Inc. has a 1 year low of $141.41 and a 1 year high of $202.04. The stock’s 50 day moving average is $184.54. The stock has a market capitalization of $95.12 billion, a price-to-earnings ratio of 48.10, a P/E/G ratio of 3.46 and a beta of 0.65. The company has a current ratio of 3.29, a quick ratio of 2.47 and a debt-to-equity ratio of 1.61.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 6th. The company reported $1.26 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.04 by $0.22. Zoetis had a net margin of 25.30% and a return on equity of 55.11%. The business had revenue of $1.87 billion for the quarter, compared to analyst estimates of $1.73 billion. During the same quarter in the previous year, the business posted $0.95 EPS. The business’s quarterly revenue was up 22.0% on a year-over-year basis. Sell-side analysts forecast that Zoetis Inc. will post 4.5 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 1st. Stockholders of record on Wednesday, July 21st will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date of this dividend is Tuesday, July 20th. Zoetis’s payout ratio is currently 25.97%.

In other Zoetis news, EVP Roxanne Lagano sold 6,000 shares of the firm’s stock in a transaction on Wednesday, May 19th. The shares were sold at an average price of $169.05, for a total transaction of $1,014,300.00. Following the completion of the transaction, the executive vice president now directly owns 53,642 shares of the company’s stock, valued at approximately $9,068,180.10. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.17% of the stock is currently owned by insiders.

A number of research firms have recently weighed in on ZTS. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $186.00 price target for the company in a report on Tuesday, June 1st. Argus upped their target price on shares of Zoetis from $185.00 to $195.00 and gave the company a “buy” rating in a report on Friday, May 28th. Barclays raised their price target on shares of Zoetis from $200.00 to $208.00 and gave the stock an “overweight” rating in a research note on Friday, May 7th. boosted their price objective on shares of Zoetis from $175.00 to $184.00 and gave the company a “neutral” rating in a research report on Wednesday, May 12th. Finally, Cantor Fitzgerald raised their target price on shares of Zoetis from $210.00 to $238.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 13th. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $188.21.

Zoetis Profile

Zoetis, Inc discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.

See Also: How are capital gains distributions different for tax-deferred account?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.